epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2021-20-2-74-82epidemiology-1228Research ArticleОБЗОРREVIEWХарактеристика эпидемиологической ситуации по эпидемическому паротиту в мире на современном этапеCharacteristics of the epidemiological situation of mumps in the world atthe present stagehttps://orcid.org/0000-0001-7657-4631ТураеваН. В.TuraevaN. V.

Наталья Викторовна Тураева, к. м. н., руководитель лаборатории профилактики вирусных инфекций

Москва

Natalia V. Turaeva, Cand. Sci. (Med.), head of the laboratory for the prevention of viral infection

Moscow

natalya-turaeva@yandex.ruhttps://orcid.org/0000-0002-5171-0286ФроловР. А.FrolovR. A.

Роман Андреевич Фролов, младший научный сотрудник лаборатории профилактики вирусных инфекций

Москва

Roman A. Frolov, junior researcher of the laboratory for the prevention of viral infection

Moscow

r.frol.8@mail.ruhttps://orcid.org/0000-0002-3810-4804ЦвиркунО. В.TsvirkunO. V.

Ольга Валентиновна Цвиркун, д. м. н., руководитель эпидемиологического отдела Московского научно-исследовательского института эпидемиологии и микробиологии им. Г. Н. Габричевского, доцент кафедры инфекционных болезней с курсами эпидемиологии и фтизиатрии Университета дружбы народов

Москва

Olga V. Tsvirkun, Dr. Sci. (Med.), head of the epidemiological Department G. N. Gabrichevsky research Institute for epidemiology and Microbiology, associate Professor at the chair of infectious diseases with courses in epidemiology and phthysiology of RUDN University

Moscow

info@gabrich.comhttps://orcid.org/0000-0002-7504-2622ГерасимоваА. Г.GerasimovaA. G.

Александра Георгиевна Герасимова, ведущий научный сотрудник лаборатории профилактики вирусных инфекций

Москва

Alexandra G. Gerasimova, leading researcher of the laboratory for the prevention of viral infection

Moscow

4521809@mail.ruФБУН «Московский НИИ эпидемиологии и микробиологии имени Г. Н. Габричевского» РоспотребнадзораРоссияG. N. Gabrichevsky Moscow Scientific Research Institute of Epidemiology and MicrobiologyRussian FederationФБУН «Московский НИИ эпидемиологии и микробиологии имени Г. Н. Габричевского» Роспотребнадзора; ФГАОУ ВО «Университет дружбы народов»РоссияG. N. Gabrichevsky Moscow Scientific Research Institute of Epidemiology and Microbiology; Peoples’ Friendship University of RussiaRussian Federation2021030520212027482Copyright © Тураева Н.В., Фролов Р.А., Цвиркун О.В., Герасимова А.Г., 20212021Тураева Н.В., Фролов Р.А., Цвиркун О.В., Герасимова А.Г.Turaeva N.V., Frolov R.A., Tsvirkun O.V., Gerasimova A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/1228

Актуальность. Социально-экономическая значимость эпидпаротита определяется осложнениями после перенесенной инфекции, оказывающими влияние на репродуктивную функцию, что влечет за собой экономические и демографические потери. Важной проблемой на сегодняшний день остается тот факт, что несмотря на высокий охват профилактическими прививками, регистрируются вспышки эпидемического паротита среди детского и молодого взрослого населения. Цель. Проанализировать эпидемическую ситуацию по эпидпаротиту в мире по данным различных литературных источников и оценить меры по контролю и борьбе с этой инфекцией. Выводы. Вспышки эпидемического паротита регистрировались среди представителей религиозных и этнических групп. Часто регистрировались вспышки в организованных студенческих и воинских коллективах, главным образом среди лиц, двукратно привитых. Наиболее пораженными вирусом паротита являлись подростки и молодые взрослые, преимущественно мужского пола. Некоторыми исследователями была показана целесообразность третьей прививки против паротита для купирования вспышек этой инфекции, но нет убедительных данных для пересмотра тактики иммунизации против эпидемического паротита по схеме из двух прививок.

Relevance. The socio-economic significance of mumps is determined by complications after a previous infection, affecting reproductive function, what entails economic and demographic losses. An important problem today remains the fact that despite high coverage with preventive vaccinations outbreaks of mumps are recorded among children and young adults. Aim. Analyze the epidemic situation with epidemic parotitis in the world according to various literary sources and evaluate measures to control and combat this infection. Conclusions. Outbreaks of mumps have been reported among religious and ethnic groups. Outbreaks were often recorded in organized student and military groups, mainly among persons twice vaccinated. The most affected by the mumps virus were adolescents and young adults, mostly males. Several researchers have shown the possibility of using a third dose of MMR vaccine to control an outbreak, but its short-term effect does not provide conclusive evidence for rethinking two-dose mumps immunization.

эпидпаротитвспышказаболеваемостьвакцинацияmumpsoutbreakincidencevaccinationReferencesWorld Health Organization (WHO). WHO vaccine-preventable diseases: monitoring systems: 2019 global summary. Geneva: WHO, 2019.World Health Organization (WHO). WHO vaccine-preventable diseases: monitoring systems: 2019 global summary. Geneva: WHO, 2019.Н. И. Брико, Г. Г. Онищенко, В. И. Покровский. Руководство по эпидемиологии инфекционных болезней. Т. 1. Москва: ООО «Издательство «Медицинское информационное агентство», 2019. Т. 1. – с. 534–543.Briko NI, Oniscshenko GG, Pokrovskiy VI. Rukovodstvo po epidemiologii infektsionnikh bolezney. Т. 1.- Moskva: ООО «Izdatel’stvo «Meditsinskoe informatsionnoe agentstvo», 2019 – s. 534–543 (In Russ.).Epidemiology and prevention of diseases that can be prevented with vaccinesEpidemiology and prevention of diseases that can be prevented with vaccinesPink Book: Course Textbook - 13th Edition (2015.). Доступно на: https://www.cdc.gov/vaccines/pubs/pinkbook/mumps.html.Pink Book: Course Textbook – 13th Edition (2015). Available at: https://www.cdc.gov/vaccines/pubs/pinkbook/mumps.htmlPlotkin’s vaccines, edited by Stanley A. Plotkin, Walter A. Orenstein,Paul A. Offit et al.: Charter 40, Mumps Vaccines, Steven A.Rubin , p.982–1018, 7th Eddition, Elsevier, 2018.Plotkin’s vaccines, edited by Stanley A. Plotkin, Walter A. Orenstein, Paul A. Offit et al.: Charter 40, Mumps Vaccines, Steven A.Rubin , p.982–1018, 7th Eddition, Elsevier, 2018.Davidkin I, Kontio M, Paunio M. MMR vaccination and disease elimination: the Finnish experience. Expert Review of Vaccines. 2010; vol. 9(9); 1045–1053.Davidkin I, Kontio M, Paunio M. MMR vaccination and disease elimination: the Finnish experience. Expert Review of Vaccines. 2010;9(9):1045–1053.Eriksen J, Davidkin I, Kafatos G, et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations. Epidemiol Infect.. 2013 Mar;141(3):651-66. doi: 10.1017/S0950268812001136. Epub 2012 Jun 12.Eriksen J, Davidkin I, Kafatos G, et al. Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations. Epidemiol Infect.. 2013 Mar;141(3):651-66. doi: 10.1017/S0950268812001136. Epub 2012 Jun 12.Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination a nine-year follow-up. Vaccine. 1995.13:1617–1622.Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination a nine-year follow-up. Vaccine. 1995.13:1617–1622.Masseria C, Mladovsky P, Hernandez-Quevedo C. The socio-economic determinants of the health status of Roma in comparison with non-Roma in Bulgaria, Hungary and Romania. European Journal of Public Health 20: 549–554.Masseria C, Mladovsky P, Hernandez-Quevedo C. The socio-economic determinants of the health status of Roma in comparison with non-Roma in Bulgaria, Hungary and Romania. European Journal of Public Health 20: 549–554.Наретя Н. Д. Влияние ревакцинации на проявления эпидемического процесса паротитной инфекции. Диссертация на соискание ученой степени кандидата медицинских наук/ФГУН «ЦНИИ эпидемиологии». Москва, 2007.Naretya ND. Vliyanie revaktsinatsii na proyavleniya epidemicheskogo processa parotitnoy infektsii. Dissetatsiya na soiskanie uchenoy stepeni kandidata meditsinskikh nauk/FGUN «Tsentralniy nauchno – issledovatelskiy institut epidemiologii». Moskva, 2007 (In Russ.).European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Mumps, Stockholm: ECDC; 2016.European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Mumps, Stockholm: ECDC; 2016.Principi N., Esposito S. Mumps outbreaks: a problem in need of solutions. Journal of Infection. 2018;76:503–506.Principi N., Esposito S. Mumps outbreaks: a problem in need of solutions. Journal of Infection. 2018;76:503–506.Marin M, Marlow M, Moore L Kelly, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of Mumps Virus-containing vaccine in persons at increased risk for Mumps during an outbreak. MMWR. anuary 12, 2018.Vol. 67/No. 1 – 33–38.Marin M, Marlow M, Moore L Kelly, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of Mumps Virus-containing vaccine in persons at increased risk for Mumps during an outbreak. MMWR/January 12. 2018;67(1):33–38.Centers for Disease Control and Prevention. National center for immunization and respiratory update on mumps epidemiology in the United States, 2017 and review of studies of 3rd dose of MMR vaccine. Mona Marin, MD Division of Viral Diseases National Center for Immunization and Respiratory Diseases CDC. ACIP Meeting June 22, 2017Centers for Disease Control and Prevention. National center for immunization and respiratory update on mumps epidemiology in the United States, 2017 and review of studies of 3rd dose of MMR vaccine.Patel M, Quinlisk P, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. The New England Journal of Medicine 2017;377; 947–956.Patel M, Quinlisk P., et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. The New England Journal of Medicine 2017;377; 947–956.Fiebelkorn AP, Coleman LA, Belongia EA, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open forum infectious diseases 2014; 1 ofu 094.Fiebelkorn AP, Coleman LA, Belongia EA, et al. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open forum infectious diseases 2014; 1 ofu 094.Morbidity and mortality weekly report. Vol. 67, № 41, Oct. 2018:1143–1146.Morbidity and mortality weekly report. Vol. 67, № 41, Oct. 2018:1143–1146.CDC. Mumps. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. Доступно на: https://www.cdc.gov/mumps/lab/qa-lab-test-infect.html.CDC. Mumps. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. Доступно на: https://www.cdc.gov/mumps/lab/qa-lab-test-infect.html.Kaaijk P, Wijmenga-Monsuur AJ, van Houten MA., et al. A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults. J Infect Dis. 2020 Mar 2;221(6):902-909. doi: 10.1093/infdis/jiz188.Kaaijk P, Wijmenga-Monsuur AJ, van Houten MA., et al. A third dose of measles-mumps-rubella vaccine to improve immunity against mumps in young adults. J Infect Dis. 2020 Mar 2;221(6):902-909. doi: 10.1093/infdis/jiz188.Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States. Science translational medicine, 2018; 10; eaao5945.Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States. Science translational medicine, 2018; 10; eaao5945.Vermeire T, Barbezange C, Francart A, et al. Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak strains. Clinical Microbiology and Infection 2019; 25: 907.e1–907.e6.Vermeire T, Barbezange C, Francart A, et al. Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak strains. Clinical Microbiology and Infection 2019; 25: 907.e1–907.e6.Anis E, Grotto I, Moerman L, et al. Mumps outbreak in Israel’s highly vaccinated society: are two doses enough. Epidemiol Infect. 2012;140(3):439–446.Anis E, Grotto I, Moerman L, et al. Mumps outbreak in Israel’s highly vaccinated society: are two doses enough. Epidemiol Infect. 2012;140(3):439–446.Stein-Zamir C, Shoob H, Abramson N, et al. Mumps outbreak in Jerusalem affecting mainly male adolescents. Euro Surveill. 2009;14(50):19440.Stein-Zamir C, Shoob H, Abramson N, et al. Mumps outbreak in Jerusalem affecting mainly male adolescents. Euro Surveill. 2009;14(50):19440.Levine H, Ankol OE, Rozhavski V, et al. Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy. Vaccine 24 mars 2011;29(15):2785–90.Levine H, Ankol OE, Rozhavski V, et al. Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy. Vaccine 24mars 2011;29(15):2785–90.

The authors declare that there are no conflicts of interest present.